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Abstract 
             Anti-mürellian hormone and Vitamin D in patients with proven breast cancer have been estimated 
to find the possibility of using such parameters as biomarkers in the diagnosis of breast cancer patients 
compared to control. 
Sera of (32) patients had been taken to estimate the levels of [AMH] & [VIT.D] at the period (March/2017-
Julyl/2017) .All studied patients samples were female with the range age (30-41) years. The present results 
showed a significance difference in statistic results at (P<0.05)of AMH & VIT.D concentration of patients 
compared to healthy control. 
The results also showed a good correlation between [AMH] & [VIT.D] of patients which the value of 
correlation is (-0.91749) at level 0.05 and o.o1. The relation between     A MH&VIT.D is inverse.  
There were( 9) patients reldettfd the samples before chemotherapy treatment and( 23) patients  dheil    
samples when they treated with chemotherapy. According to t-test there was significant difference in both 
[AMH] & [VIT.D]  between the previous groups at level (0.05). 
        So this study recommended to use [AMH] & [VIT.D]  in early detecting of the breast cancer disease in 
women at fertile age . 
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لاصلاخة  
 نومرى نم لكل يمكلا باسحلا ةساردلا تنيبHMA  نيماتيفوD  ةعومجم عم ونراقملأ تمت دقو يدثلا ناطرس ىضرم مد لصم يف
 ءاحصلأا صاخشلأا نم ةرطيسلا . ناطرس ضرم صيخشت يف ةميم ةيويح تارشؤمك نيمماعلا نم لاك دامتعا ةساردلا نم فديلا ناكو
  يدثلا. 
/ راذآ نيب ةدتمملا وينمزلأ ةرتفلا يف ثحبلا ءارجإ مت دقل2012/زومتو2012  عمج ايللاخ مت32  ىضرمل مدلا لصم نم ونيع
(نم رامعلأل ثانلإا نم يدثلا ناطرس30-42(رامعلأا نم ءاحصلأا ثانلإا نم تناكف ةرطيسلا ةعومجم امأ اماع )22-41 عقاوب اماع )
32  كلذك ونيع . جئاتنلا تريظأ ءاحصلأاو ىضرملا تاءارق نيب ونراقملأ دنع ءاصحلإا جئاتن يف ةيئاصحإ ةللاد تاذ قورف دوجو ةيلاحلا
نم لكل  نومرىHMA  نيماتيفوD دنع P<0.05 . 
 نومرى نيب هديج ةطبارتم ةقلاع جئاتنلا تريظأوHMA  نيماتيفوD  مد لصم يف(-0.91749)  دنع0.01  و0.05  ىضرملا
ب ةقلاعلا ربتعت ثيحةيسكع اميني.                                                                                                             
 ذخا متو2 لوصحلا دعبو لبق تاءارقلا نيب يونعم قرف كانى ناكو ويمع ايلوصح دعبو يواميكلا جلاعلا ىمع ايلوصح لبق تانيع
دنع يواميكلا جلاعلا ىمع0.05. 
 نومرى مادختساب يصوأ ينأف ةساردلا هذيل اقبطوHMA  نيماتيفوD ةبوصخلا رمع يف ءاسنمل يدثلا ناطرس نع ركبملا فشكلا يف 
 
 تاممكلالا:هيحاتفم  تارشؤمةيويح ،AMH نيماتيف،Dيدثلا ناطرس،.  
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Introduction 
1.1 BREAST CANCER: 
Breast cancer is' a kind of cancer. that develops‟ from breast cells. Breast cancer is cancer 
that „develops from breast tissue) NCI. , 2014(. 
Signs of breast cancer; may include. a lump in the breast, a change, in breast shape, 
dimpling; of the skin, fluid coming, from the nipple, or a red scaly, patch of skin )NCI., 
2014(.In those with distant spread of the disease, there may be bone, pain, swollen 
lymph, nodes, shortness of, breath, or yellow skin. 
  Breast cancer, is the, leading cause of cancer in young women, accounting for 25% 
of cases diagnosed, by age 40) Dev, 2012  ( , young, breast cancer patients, face a myriad 
of. Challenges, including decisions on, preserving, fertility prior to cancer treatment. It is 
well established.Anti-mürellian Hormone, Testing of Ovarian Reserve  (Taguchi ,2010(. 
    AMH or Anti-müllerian hormone is a protein. Hormone produced by granulose 
cells (cells lining the egg sacs or follicles) within the, ovary. AMH can be measured in 
the blood at any time in the menstrual, cycle as it is stable throughout, the cycle. It is a 
marker for ovarian (egg), reserve. Also known, by various other names, is a glycoprotein 
hormone from the transforming growth, factor beta super family, whose key roles are in 
growth differentiation and folliculogenesis. .)Richard , 2008 ( 
    It is first. made in primary, follicles that advance from the primordial follicle 
stage. At these stages follicles are microscopic and cannot be seen by ultrasound .)Warne 
& Fairley, 1973; Su & Sammel , 2010) 
    AMH production is highest, in prenatal and, small,natal stages (less than 4mm 
diameter) of, development. 
    Production, decreases and, then pause as follicles grow. There is nearly no 
AMH;made in follicles over,8mm. 
That chemotherapy, used to treat;breast cancer, incurs; damage to the ovarian 
reserve, or the quantity, and quality of, remaining oocytes (Warne & Fairley , 1973) 
resulting in loss of fertilityand premature ovarian failure  impacts ovarian reserve. 
(Partridge , 2008(. 
, suggesting an independent effect of malignancy on reproductive potential. As more 
female breast cancer patients consider future fertility, it is important to, determine; if 
ovarian‟ reserve is affected, by cancer, prior to any, therapeutic, intervention. This will 
allow us to better understand the interplay between cancers and, more female breast 
cancer patient Partridge AH, Gelber s consider future. 
Ovarian,reserve is measured by hormone and, ultrasound, biomarkers, including 
Anti-mürellian hormone (AMH), follicle stimulating hormone (FSH), inhibin B (inhB) 
and natal‟follicle count; (AFC), (Gelber 2008). Among these measures, AMH; is a 
good;candidate biomarkerbecause it is relatively; stable across the menstrual cycle and 
has been associated with, reproductive outcomes; from; time to menopause to assisted 
reproduction (ART), responses innormal, and; infertile;, women. (Broekmans, 2007) 
  Vitamin D: is the name given, to a group of; fat-soluble; prohormones (substances 
that usually have little; hormonal activity by; themselves but that the body can turn into 
hormones). Vitamin D;aids the body; use calcium and phosphorus to make strong bones 
and; teeth. Skin exposed to sunshine can;create vitamin D, and vitamin D can also be 
obtained from certain foods. Vitamin D deficiency can cause a weakening, of the bones 
that is called rickets in children and osteomalacia in adults. 
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      Two main composes of vitamin D that are substantial to humans are vitamin D2, 
or ergocalciferol, and vitamin D3, or cholecalciferol. Vitamin D2 is made/naturally/ by 
plants, and vitamin D3 is made; naturally by the body; when skin islexposed to ultraviolet 
radiation, in sunlight. Both forms are converted to 25-hydroxyvitamin D in the liver. 25-
Hydroxyvitamin D then travels through the blood to the kidneys, where it is further 
modified to 1, 25-dihydroxyvitamin D, or calcitriol, the; active form of vitamin D in the 
body. The most accurate; method of evaluating a person‟s vitamin D status is to measure 
the level of 25-hydroxyvitamin D in; the blood. 
Vitamin D‟s most; important role, in the; human body is to keep bones; healthy and 
strong by helping the; body; absorb calcium. 
     However, recent; research has pointed;to additional; ways that; vitamin D 
deficiency factors, into our overall; health, including; its role in chronic diseases like 
diabetes, autoimmune disease,obesity, cardiovascular disease and cancer, as well as an 
association with a higher risk of; both overall and cancer; mortality. Instead‟ of only 
affecting ;cells that live inl the bone. Vitamin D is able to affect many different, types of 
cells in different organs in the body. The way it does this is by, turning genes within that 
cell, “on and off.” In other words, vitamin D affects the way a cell perform sits function, 
and it can control the growth or the death of that cell. 
Many studies have latterly concentrated on the relationship of vitamin D levels to 
cancer. Low Vitamin D levels have been correlated with a 30 to 50 percent increased risk 
of colon, prostate and breast cancer.(Otten &  Hellwig, 2006; Michaelsson, 2010) 
   The cancers for which the most human data are available are colorectal, breast, 
prostate, and pancreatic cancer. Numerous epidemiologic studies have shown that higher 
intake or blood levels of vitamin D are associated with a reduced risk of colorectal 
cancer. (Kinuta . 2000; Yoshizawa, 1997). Taking into account that knock-out 
experiments have shown that vitamin D receptor null mice not only experience uterine 
hypoplasia but also impaired folliculogenesis, it might be hypothesized that vitamin D 
deficiency may have a detrimental effect on female ovarian reserve. This may be further 
supported by previous reports demonstrating that serum 25-OH Vitamin D levels 
correlates with antimullerian hormone (AMH) levels in women of advanced reproductive 
age. 
In humans, the vitamin D receptor is present in many female organs, including the 
ovary, uterus, and placenta.# The active form of vitamin D (Calcitriol) has many roles in 
female reproduction. Bound to its receptor, Calcitriol is able to control the genes involved 
in making estrogen.v The uterine lining produces Calcitriol in response to the embryo as 
it enters the uterine cavity, shortly before implantation.#Calcitriol controls several genes 
involved in embryo implantation.# Once a woman becomes pregnant, the uterus and 
placenta continue to make calcitriol, which helps organize immune cells in the uterus, so 
that infections can be fought without harming the pregnancy. Poor vitamin D status has 
been associated with certain pregnancy complications such as gestational hypertension 
and diabetes. 
Hypothesis )Gandini, 2011; Woolcott, 2010; Jenab, 2010; Ozkan, 2010; Nikolaos 
2008(. 
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.2 Matrials & Methods 
2.1. Ethical Approval 
A valid consent was achieved from hospital administration and from each female 
(patients and controls) before their inclusion in the study. For every female or her 
followers, the procedure had been informed before the samples were collected, making 
absolutely sure that they understood the procedure that was to be carried 
 
2.2 Sample Collection 
Thirty two patients, female only with diagnosed breast cancer in deferent stages with 
range of age between (31-42) years and thirty two healthy female hn control with  na age 
range (29-41) years which they are volunteers. The patients were visitors for cancer 
center la Marjan Teaching Hospital in Hilla city. 
 
2.3 Collection Of Blood And Serum Preparation: 
          Blood samples were obtained from patients and control group. The vein on the 
front of elbow forearm is all most employer. The tourniquet was put around the arm and 
applied procedure on the area vein with iodine disinfected then drawn 5mL of blood. 
Then put the samples from 10 -20 minutes after that the components of blood were 
separated by centedfuge instrument to get on serum. 
 
2.4 Procedure Of Amh Test:  
Enzyme Immunoassay for the quantitative Determination of Anti-mürellianhormone 
(UNION-AMH) in BIOTEECH Manufactures is the kit that used to determine 
S.AMH.Expected values for females in age range (31-40) years are (0.14-10.40) ng/mL                                               
AMH was measured by Immunology analyzer (union instrument made in China).  
 
2.5 Procedure Of Vitamine D Test: 
MAGLUMI 25-OH Vitamin D (CLIA) Kit has  been designed for the quantitative 
determination of 25-OH Vitamin D IN HUMAN SERUM.Normal value of VIT.D 
between  ( 30-100) ng/mL. 
The test has to be performed on MAGLUMI FULLY –Chemiluminescence 
immunoassay (CLIA) analyzer MAGLUMI (Including Maglumi 600,Maglumi 
1000,Maglumi 1000 Plus, Maglumi 2000,Maglumi 2000 Plus,Maglumi 3000 and 
Maglumi 4000).  
 
3-Resulte And Descussion 
Serum Anti-Mürllain hormone and Vitamin D levels were determined as follows: 
From 64
th
 samples were collected selectively at age between 29-42 years 32 samples of 
patients and 32 samples of healthy control. There were 9 patient samples collected before 
taking chemotherapy and other samples were collected after chemotherapy treatment 
.Most results are offered  as mean ± standard deviation (SD).The statistical significance 
was accepted when probability  p<0.05 and p<0.01 .Analysis ih achieved employing the 
Microsoft Excel 2010. 
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3.1. AMH Concentration In Serum: 
       The mean of AMH concentration in serum had shown decrease in patients of breast 
cancer in comparison to that healthy control  
 
Table 1: The level of [AMH] in both patients and control: 
GROUPS COUNT  MEAN  ± SD ng/mL RANGE OF 
AGE 
 
 AMH of patient 32 0.06       ± 0.019007  30_42 YEARS P ᷾<0.05 
AMH of Control 32 6.4813   ± 1.5  29_41 YEARS  
 
According to descriptive statics and t.test two samples mean and Anova Two-factor 
without replication (between groups) ;there‟sa significance difference between mean of 
patients and mean of control 
Anti-Müllerian hormone (AMH) levels fall during chemotherapy. Treatment-induced 
amenorrhea is a reversible phenomenon, but few data are available on long-term AMH 
changes in breast cancer.)Institute of Medicine .National Academy Press, 2010(. 
 
 
3.2 Vit.D Concentration In Serum: 
The mean of VIT.D concentration in serum had shown decrease in patient of breast 
cancer in comparison to that healthy control .                                                             
 
Table 2: The level of [VIT.D] in both patients and control. 
GROUPS COUNT MEAN± SD RANGE 
OF AGE 
 
VIT. D of Patient 32 6.35 ± 2.85431 
ng/mL 
30_42 P<0.05 
VIT.D of Control 32 41.219± 9.07607 
ng/mL 
29_41  
According to descriptive statistics and t.test two samples mean and Anova two- 
factors without replication there‟s significance difference between mean of Vit.D of 
patients and control. 
Experimental evidence has also suggested a possible association between vitamin D 
and cancer risk. In studies of cancer cells and of tumors in mice, vitamin D has been 
found to have several activities that might slow or prevent the development of cancer, 
including promoting cellular differentiation, decreasing cancer cell growth, stimulating 
cell death (apoptosis), and reducing tumor blood vessel formation (angiogenesis). 
)Cranney, 2007;  Holick, 2006. Anne-Sophie, 2014; Thorne, 2008  ( . 
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3.3 Correlation Between [AMH] And [VIT.D]: 
The mean of [AMH] and the mean [VIT.D] had shown correlation between the both 
parameters . 
 
Table 3: The Correlation Between [AMH] and [VIT.D] 
GROUPS MEAN± SD CORRELATION 
[AMH]  PATIENT SAMPLE 0.06 ± 0.01 9007 
ng/mL 
-0.91749 
 
[VIT.D ] PATIENT SAMPLE 6.35 ± 2.85431 ng/mL  
 
According to data analysis of micro soft Excel 2010 and spss16 ,there‟s 
significance correlation between  AMH & VIT.D concentration at level 0.05 and o.o1. 
The relation between AMH &VIT.D is inverse. New research finds that low levels of 
vitamin D influence AMH test  results. In fact, if the individual has low vitamin D, the 
individual  could end up with a false positive for low AMH.)Moreno, 2005(. 
 
 The next figure shows the correlation between [AMH] & [VIT.D]. 
 
 
 
Figure No 1: Correlation Between [AMH] & [VIT.D] OF PATIENTS 
 
 
3.4.Effect Of Chemotherapy Treeatment: 
       There were many patient samples collected before taking chemotherapy and other 
samples were collected after chemotherapy treatment . The next table shows the effect of 
chemotherapy on serum [AMH] of patients. 
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Table 4: Effect of chemotherapy on serum [AMH] of patients 
GROUPS No.of 
cases 
MEAN± 
ng/ml 
Std.S T.test 
probability 
 
Patients without 
chemotherapy 
 
9 0.0755 ± 0.0174  0.0062203 P<0.05 
  Patients with   
chemotherapy 
 
23 0.06 ± 0.01901   
 
According to t.test the previous table shows the difference in means between the two 
groups of patients ,there were significance difference between them.   
Anti-Müllerian hormone (AMH) levels fall during chemotherapy. Treatment-induced 
amenorrhea is a reversible phenomenon, but few data are available on long-term AMH 
changes in breast cancer.)Volpe, A Hum repro'd Update, 2010; 16(2): 113–130(.  
 
Table 5:effect of chemotherapy on serum [VIT.D] OF PATIENTS: 
GROUPS NO.of 
cases 
MEAN± Std.S T.test 
probability 
 
Patient without 
chemotherapy 
9 8.8111± 1.40128ng/ml 0.0000367 P<0.05 
Patient with 
chemotherapy 
23 5.25416± 2.90075ng/ml   
 
According to t.test there were significance difference between patients not treated 
with chemotherapy and patients treated with chemotherapy. 
Drugs, and particularly chemotherapy drugs can deplete vitamin D levels. And good 
vitamin D levels are essential to prevent many different illnesses from Alzheimer´s to 
Ricketts and bone weakness in old age. )Holt , 2002  ( . 
Importantly, chemotherapy can reduce vitamin D to dangerously low levels in the 
bodies of cancer patients, causing severe vitamin D deficiency. And this happens at 
exactly the moment good vitamin D levels are crucial to a cancer patient. In February 
2009, researchers from Roswell Park Cancer Center, studying patients with colorectal 
cancer, noted that vitamin D deficiency was linked to a heightened risk of the disease and 
lowered survival. They then showed that chemotherapy was associated with „severe 
vitamin D deficiency‟. Each of three different chemotherapy treatments studied reduced 
plasma vitamin D levels down to 21.3 ng/ml, where 30-50 is an optimal range. The 
researchers recommended that colorectal cancer patients should be considered for 
„aggressive vitamin D replacement strategies. 
A 2016 study on breast cancer by Dr. William Jacot and colleagues from Montpelier, 
France showed that „tailored vitamin D supplementation‟ could keep plasma levels in the 
acceptable range in women with breast cancer even during chemotherapy. This followed 
2012 research. 
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4. Concolusion 
According to this study, there were a relation between the concentration of 
Antimülline hormone and breast cancer patients, also there were a relation between the 
concentration of Vitamin D and breast cancer patient. 
Both of [AMH] and [VIT D] are lowered in breast cancer patient.There is an is 
inverse correlation between  [AMH] and [VIT D]. 
Chemotherapy affected on [AMH] and [VIT D] which lowered them concentrations. 
 
5.Recomendation 
The parameters [AMH] and [VIT.D] can be used as biomarkers for breast cancer 
patients. 
Study other markers related to breast cancer for early detection and management of the 
disease. 
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